fc 777 casino login philippines app

fc 777 casino login philippines app AT&T Announces Plan to Phase Out Copper Landline Service by 2029, California Exempted Due to Legal Protections

Aurobindo inks pact with global pharma major for respiratory products

Special counsel moves to dismiss election interference case against President-elect Donald Trump

RACHEL Reeves boldly insisted last night there will be no further tax rises during her time as Chancellor. Her dramatic claim to a frosty reception from business leaders came as McVitie’s biscuit chief said Britain was becoming a less attractive place to invest. Reeves , whose pledge makes her a hostage to fortune, vowed she has “wiped the slate clean” after £40 billion of tax hikes at the Budget last month. But her intervention comes as Tory leader Kemi Badenoch refused to say if she would reverse changes. Ms Reeves told the CBI business summit that she hadn’t heard “many alternatives” after facing claims firms were being used as cash cows. She said: “I faced a problem, and I faced into it, and we have now drawn a line under the fiction peddled by the previous government. read more on politics “We’ve put our public finances back on a firm footing, and we’ve now set the budgets for public services for the duration of this Parliament. “Public services now need to live within their means because I’m really clear, I’m not coming back with more borrowing or more taxes.” In a boost to the public and business, she added that “we’re never going to have to do a budget like that again ”. But her comments came after Rain Newton-Smith, CBI chief executive, said that “tax rises like this must never again be simply done to business”. Most read in Money And the chief executive of the firm behind brands such as McVitie’s and Jacob’s also said the UK was less attractive to do business . Salman Amin, boss of Pladis, said: “Historically we’ve been super bullish on the United Kingdom. In fact, by far, the greatest investment across all of our countries over the last decade or so has come to the UK. “So we’ve been a very major investor in the UK. We would like to continue to be a major investor going forward. It’s becoming harder to understand what the case for investment is.” A Confederation of British Industry survey of 266 firms found 62 per cent were likely to reduce the number of new hires as a result of the NI hike while almost half - 48 per cent - would reduce their current headcount. However, Tory leader Ms Badenoch refused to say whether she would reverse the rise in employers’ national insurance at the Budget. She told Sky News that she would likely change the policy but wouldn’t comment on “every bit of micropolicy”. The Chancellor has also been under pressure after imposing changes to inheritance tax that will hit farmers and taking away universal winter fuel payments.Mutual of America Capital Management LLC Trims Holdings in PDF Solutions, Inc. (NASDAQ:PDFS)

Rhode Island beats Bryant 35-21 to claim its first Coastal Athletic Association title

Jeremiyah Love basked in both his accomplishment and the congratulatory screams and shouts of his teammates. Moments earlier, the sophomore running back had taken the handoff from Riley Leonard, accelerated through a hole and sprinted 68 yards into the end zone. One hundred years, one month, and five days — or, for the exacting, 36,561 days — later, the descendants found the proper way to pay homage to their forefathers. By doing what their ancestors did so long ago: Beating their forever rival. No. 6 Notre Dame reinforced its claim for a berth in the College Football Playoff by routing previously unbeaten No. 19 Army, 49-14, Saturday night at Yankee Stadium. In what was a mostly complete performance, the Fighting Irish (10-1) rolled up 464 yards of total offense against an Army (9-1) squad that entered the contest allowing opponents 10.3 points per game, which was tied for the fewest in the nation with Ohio State. Notre Dame finished the game with 275 yards on the ground and five rushing touchdowns. Love ran for 130 yards and two touchdowns on seven carries. Jadarian Price added 53 yards on 10 carries and two scores. Aneyas Williams recorded 62 yards and a touchdown on three carries. They weren’t the Four Horsemen, but the triumvirate more than sufficed. The nationally televised primetime showcase was the centerpiece of Notre Dame’s centennial celebration of the school’s 13-7 win over Army at the Polo Grounds on Oct. 18, 1924. What took place over the course of three hours in the ballyard in the Bronx on a clear, cool night bore little resemblance to the epochal matchup in the Polo Grounds. Because, in part, the forward pass was utilized. Particularly by the Irish as Leonard threw touchdown passes of 28 yards to Jordan Faison and 6 yards to Love on Notre Dame’s first two possessions of the game. Leonard completed 9-of-11 passes for 130 yards and the two scores in the first half. The senior finished the game 10-for-13 for 148 yards and two touchdowns before being replaced by sophomore Steve Angeli late in the third quarter. Angeli was 4-for-5 for 41 yards. The Black Knights cut the deficit to 14-7 early in the second quarter on quarterback Bryson Daily’s 4-yard touchdown run. And when Army stopped Love on fourth-and-goal from the 1-yard line on the ensuing possession, a murmur rumbled amongst the partisan crowd. Could the visiting Black Knights — Notre Dame was the home team for this game — pull the upset? The Irish answered the question definitively by forcing Army into a three-and-out and, when they regained possession of the ball, Love atoned with a 14-yard touchdown jaunt which was the culmination of Notre Dame’s three-play, 41-yard drive. Price’s 2-yard touchdown run with 26 seconds remaining sent the Irish into halftime with a 28-7 lead. Notre Dame had an insurmountable advantage. So with the result essentially accounted for, it was time for the Irish to do some resume building and statement making ahead of the playoff games they hope to find themselves in. And on the first play from scrimmage in the second half Love began and finished his 68-yard expedition through Army’s defense. Which was bookended by Price’s 10-yard touchdown run at the end of the third quarter that stretched Notre Dame's lead to 42-7. Williams’ 58-yard touchdown run early in the fourth quarter ballooned the Irish’s advantage to 49-7. Daily’s 1-yard touchdown plunge with 22 seconds left ended the scoring. Daily accounted for 139 of Army’s 207 rushing yards. He also completed 4-of-8 passes for 26 yards. The Black Knights totaled 233 yards of offense. Notre Dame kicker Mitch Jeter missed a 48-yard field goal at the end of the first half, and had his 30-yard attempt midway through the third blocked.

Watch: Drug dealer caught red-handed with cocaine by police inside underpass

ATLANTA , Nov. 26, 2024 /PRNewswire/ -- Atomic-6 was recently awarded a Tactical Funding Increase (TACFI) to further develop its revolutionary Space ArmorTM shielding tiles and complete testing qualification for first flight. Designed to minimize shielding mass, stowage space, post-impact ejecta, and mission risk, Space ArmorTM provides vital protection for space assets against space debris and kinetic energy weapons while offering optional radio frequency permeable capabilities. This innovative technology is essential for maintaining the United States' competitive edge in space operations, a concern that has been increasingly emphasized by Pentagon officials and lawmakers. In NASA's recent study on the economic advantages of safeguarding satellites from orbital debris, the findings suggest potential net benefits exceeding $50 billion over the next 30 years. To meet this demand, Space ArmorTM offers two levels of protection: Lite and Max. "Space ArmorTM Lite" is designed to withstand impacts from debris up to 3mm, which accounts for over 90% of debris in low earth orbit, while "Space ArmorTM Max" is designed to withstand impacts from debris up to 12.5mm. This productized approach allows for tailored protection strategies, ensuring both cost-effectiveness and critical defense against varying sizes of debris. The TACFI award, along with matching funds from outside investors, paves the way for Atomic-6 to take Space ArmorTM from prototype to full product line with added variations and capabilities to meet market and customer demand. Atomic-6 is committed to the safety, sustainability, performance and affordability of future space endeavors. Space ArmorTM is the latest of several Atomic-6 innovations to reinforce their mission and provide the US military, Allies, and commercial space operators with the strategic edge necessary to reduce mission risk and protect space assets. Contact Us for RFPs To learn more about Space ArmorTM, other Atomic-6 innovations, and/or submit a Request for Proposal (RFP), please contact our team at sales@atomic-6.com . About Atomic-6 Atomic-6 is revolutionizing mobility in space, air, land, and sea by rapidly designing and manufacturing the world's finest composite solutions. Everything we touch gets lighter, stronger, and smarter. Visit our website atomic-6.com or contact us directly to learn more. Media Inquiries Atomic-6, Inc. media@atomic-6.com View original content to download multimedia: https://www.prnewswire.com/news-releases/atomic-6-secures-3-8m-tacfi-for-space-armor-302316953.html SOURCE Atomic-6ALTOONA, Pa. — After UnitedHealthcare’s CEO was gunned down on a New York sidewalk, police searched for the masked gunman with dogs, drones and scuba divers. Officers used the city's muscular surveillance system. Investigators analyzed DNA samples, fingerprints and internet addresses. Police went door-to-door looking for witnesses. When an arrest came five days later, those sprawling investigative efforts shared credit with an alert civilian's instincts. A Pennsylvania McDonald's customer noticed another patron who resembled the man in the oblique security-camera photos that New York police had publicized. Deputy Commissioner of Operations Kaz Daughtry speaks during a press conference regarding the arrest of suspect Luigi Mangione, Monday, Dec. 9, 2024, in Hollidaysburg, Pa., in the fatal shooting of UnitedHealthcare CEO Brian Thompson. (AP Photo/Ted Shaffrey) Luigi Nicholas Mangione, a 26-year-old Ivy League graduate from a prominent Maryland real estate family, was arrested Monday in the killing of Brian Thompson, who headed one of the United States’ largest medical insurance companies. He remained jailed in Pennsylvania, where he was initially charged with possession of an unlicensed firearm, forgery and providing false identification to police. By late evening, prosecutors in Manhattan had added a charge of murder, according to an online court docket. He's expected to be extradited to New York eventually. It’s unclear whether Mangione has an attorney who can comment on the allegations. Asked at Monday's arraignment whether he needed a public defender, Mangione asked whether he could “answer that at a future date.” Mangione was arrested in Altoona, Pennsylvania, after the McDonald's customer recognized him and notified an employee, authorities said. Police in Altoona, about 233 miles (375 kilometers) west of New York City, were soon summoned. This booking photo released Monday, Dec. 9, 2024, by the Pennsylvania Department of Corrections shows Luigi Mangione, a suspect in the fatal shooting of UnitedHealthcare CEO Brian Thompson. (Pennsylvania Department of Corrections via AP) They arrived to find Mangione sitting at a table in the back of the restaurant, wearing a blue medical mask and looking at a laptop, according to a Pennsylvania police criminal complaint. He initially gave them a fake ID, but when an officer asked Mangione whether he’d been to New York recently, he “became quiet and started to shake,” the complaint says. When he pulled his mask down at officers' request, “we knew that was our guy,” rookie Officer Tyler Frye said at a news conference in Hollidaysburg. New York Police Commissioner Jessica Tisch said at a Manhattan news conference that Mangione was carrying a gun like the one used to kill Thompson and the same fake ID the shooter had used to check into a New York hostel, along with a passport and other fraudulent IDs. NYPD Chief of Detectives Joseph Kenny said Mangione also had a three-page, handwritten document that shows “some ill will toward corporate America." A law enforcement official who wasn’t authorized to discuss the investigation publicly and spoke with The Associated Press on condition of anonymity said the document included a line in which Mangione claimed to have acted alone. “To the Feds, I’ll keep this short, because I do respect what you do for our country. To save you a lengthy investigation, I state plainly that I wasn’t working with anyone,” the document said, according to the official. It also had a line that said, “I do apologize for any strife or traumas but it had to be done. Frankly, these parasites simply had it coming.” Pennsylvania prosecutor Peter Weeks said in court that Mangione was found with a passport and $10,000 in cash — $2,000 of it in foreign currency. Mangione disputed the amount. Thompson, 50, was killed last Wednesday as he walked alone to a midtown Manhattan hotel for an investor conference. Police quickly came to see the shooting as a targeted attack by a gunman who appeared to wait for Thompson, came up behind him and fired a 9 mm pistol. Investigators have said “delay,” “deny” and “depose” were written on ammunition found near Thompson’s body. The words mimic a phrase used to criticize the insurance industry. From surveillance video, New York investigators gathered that the shooter fled by bike into Central Park, emerged, then took a taxi to a northern Manhattan bus terminal. Once in Pennsylvania, he went from Philadelphia to Pittsburgh, “trying to stay low-profile” by avoiding cameras, Pennsylvania State Police Lt. Col. George Bivens said. A grandson of a wealthy, self-made real estate developer and philanthropist, Mangione is a cousin of a current Maryland state legislator. Mangione was valedictorian at his elite Baltimore prep school, where his 2016 graduation speech lauded his classmates’ “incredible courage to explore the unknown and try new things.” He went on to earn undergraduate and graduate degrees in computer science in 2020 from the University of Pennsylvania, a spokesperson said. “Our family is shocked and devastated by Luigi’s arrest,” Mangione’s family said in a statement posted on social media late Monday by his cousin, Maryland lawmaker Nino Mangione. “We offer our prayers to the family of Brian Thompson and we ask people to pray for all involved.” An NYPD police officer and K-9 dog search around a lake in Central Park, Monday, Dec. 9, 2024, in New York. (AP Photo/Yuki Iwamura) Luigi Nicholas Mangione worked for a time for the car-buying website TrueCar and left in 2023, CEO Jantoon Reigersman said by email. From January to June 2022, Mangione lived at Surfbreak, a “co-living” space at the edge of Honolulu tourist mecca Waikiki. Like other residents of the shared penthouse catering to remote workers, Mangione underwent a background check, said Josiah Ryan, a spokesperson for owner and founder R.J. Martin. “Luigi was just widely considered to be a great guy. There were no complaints,” Ryan said. "There was no sign that might point to these alleged crimes they’re saying he committed.” At Surfbreak, Martin learned Mangione had severe back pain from childhood that interfered with many aspects of his life, from surfing to romance, Ryan said. “He went surfing with R.J. once but it didn’t work out because of his back," Ryan said, but noted that Mangione and Martin often went together to a rock-climbing gym. Mangione left Surfbreak to get surgery on the mainland, Ryan said, then later returned to Honolulu and rented an apartment. Martin stopped hearing from Mangione six months to a year ago. Although the gunman obscured his face during the shooting, he left a trail of evidence in New York, including a backpack he ditched in Central Park, a cellphone found in a pedestrian plaza, a water bottle and a protein bar wrapper. In the days after the shooting, the NYPD collected hundreds of hours of surveillance video and released multiple clips and still images in hopes of enlisting the public’s eyes to help find a suspect. “This combination of old-school detective work and new-age technology is what led to this result today,” Tisch said at the New York news conference. ___ Scolforo reported from Altoona and Hollidaysburg, Pennsylvania. Contributing were Associated Press writers Cedar Attanasio and Jennifer Peltz in New York; Michael Rubinkam and Maryclaire Dale in Pennsylvania; Lea Skene in Baltimore and Jennifer Sinco Kelleher in Honolulu. Get local news delivered to your inbox!

NoneThese results were presented today after market close at an AACR Special Conference in Cancer Research. The company will also hold a webinar on December 10 at 6:30 AM MT / 8:30 AM ET / 1:30 PM GMT to present the preliminary data broadcast from Recursion's X (formerly Twitter), LinkedIn, and YouTube accounts with an opportunity to submit questions here . "Cell cycle dysregulation and transcriptional 'addiction' are both hallmarks of many aggressive cancers," said David Hallett, Ph.D., Chief Scientific Officer of Recursion. "By inhibiting CDK7, we have the potential to target both mechanisms while fine tuning the therapeutic index. Using our precision design platform, we created a molecule with rapid oral absorption to reduce GI tissue exposure, a suitable half life to manage side effects, and target engagement covering the IC80 level." ELUCIDATE is an ongoing Phase 1/2 study evaluating the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and maximum tolerated dose (MTD) of REC-617 in patients with advanced solid tumors. As of the November 15, 2024 data cutoff, preliminary findings include 18 patients with advanced solid tumors who were response evaluable in the monotherapy dose-escalation phase. Doses ranged from 2 mg to 20 mg once daily (QD) and 1 mg twice daily (BID). REC-617 was generally well-tolerated across all dose levels, with no discontinuations due to adverse events (AEs). Adverse events to date were predominately Grade 1-2, on-target, and reversible. An MTD has not yet been reached. While efficacy was not an endpoint in this Phase 1 study, or anticipated in monotherapy, a confirmed durable partial response (PR) by RECIST on REC-617 monotherapy was achieved in a patient with metastatic, platinum-resistant ovarian cancer. The response is on-going after more than 6 months of treatment. This patient had progressed following 4 lines of prior therapy in the advanced setting. In addition, four patients achieved a best response of stable disease (SD) across multiple dose levels for up to 6 months of treatment. "These initial findings for REC-617 represent an exciting step forward in the development of CDK7 inhibitors, with a favorable PK/PD profile and a durable confirmed partial response observed in dose escalation in a highly pre-treated patient population," said Najat Khan, Ph.D., Chief R&D Officer and Chief Commercial Officer, Recursion. "Designed using our AI-powered OS platform, REC-617 reflects our focus on enhancing the therapeutic index to deliver more effective and safer treatment options for patients. We are eager to continue this momentum in dose escalation and to initiate the next phase of the program next year." In parallel to the ongoing monotherapy dose escalation (QD and BID), combination studies are expected to initiate for ELUCIDATE in H1, 2025. The company expects to present additional ELUCIDATE as well as preclinical REC-617 data at future medical meetings. Summary of Interim REC-617 Monotherapy Dose Escalation Results Study Design & Demographics REC-617 is a potential best-in-class CDK7 inhibitor, precision designed using AI-led approaches, with only 136 novel molecule synthesized from hit to candidate identification in less than 12 months. The molecule is designed to maximize its therapeutic index by enabling the tight control of both the extent and duration of target inhibition. CDK7 inhibition combines many potential benefits such as transcription inhibition, reduction of aberrant kinome activation, cell cycle inhibition, and modulation of estrogen receptor activity. This makes it an attractive target to overcome common resistance pathways associated with CDK4/6 inhibition, which only targets the cell cycle. About ELUCIDATE REC-617 is currently being evaluated as a monotherapy in the ELUCIDATE trial. ELUCIDATE is a multicenter, open-label, two-stage clinical trial to evaluate safety, pharmacokinetics, pharmacodynamics, and efficacy of REC-617 in advanced solid tumors, including non-small cell lung cancer (NSCLC), colorectal cancer, breast cancer, pancreatic cancer, ovarian cancer, head and neck cancer. Both the monotherapy and combination therapy dose escalation portion of the trial will enroll patients across multiple dose levels to determine the optimal biological dose (OBD). The dose expansion phase of the trial will commence upon identification of the OBD. The primary efficacy endpoint of the expansion phase is objective response rate (ORR). About Recursion Recursion (NASDAQ: RXRX) is a clinical stage TechBio company leading the space by decoding biology to radically improve lives. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously generate one of the world's largest proprietary biological and chemical datasets. Recursion leverages sophisticated machine-learning algorithms to distill from its dataset a collection of trillions of searchable relationships across biology and chemistry unconstrained by human bias. By commanding massive experimental scale - up to millions of wet lab experiments weekly - and massive computational scale - owning and operating one of the most powerful supercomputers in the world, Recursion is uniting technology, biology and chemistry to advance the future of medicine. Recursion is headquartered in Salt Lake City, where it is a founding member of BioHive, the Utah life sciences industry collective. Recursion also has offices in Toronto, Montréal, New York, London, Oxford area, and the San Francisco Bay area. Learn more at www.Recursion.com , or connect on X (formerly Twitter) and LinkedIn. Media Contact [email protected] Investor Contact [email protected] Forward-Looking Statements This document contains information that includes or is based upon "forward-looking statements” within the meaning of the Securities Litigation Reform Act of 1995, including, without limitation, those regarding the potential efficacy of REC-617; timing of the Phase 1/2 clinical trial of REC-617; early and late stage discovery, preclinical, and clinical programs; licenses and collaborations; prospective products and their potential future indications and market opportunities; Recursion OS and other technologies; business and financial plans and performance; and all other statements that are not historical facts. Forward-looking statements may or may not include identifying words such as "plan,” "will,” "expect,” "anticipate,” "intend,” "believe,” "potential,” "continue,” and similar terms. These statements are subject to known or unknown risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such statements, including but not limited to: challenges inherent in pharmaceutical research and development, including the timing and results of preclinical and clinical programs, where the risk of failure is high and failure can occur at any stage prior to or after regulatory approval due to lack of sufficient efficacy, safety considerations, or other factors; our ability to leverage and enhance our drug discovery platform; our ability to obtain financing for development activities and other corporate purposes; the success of our collaboration activities; our ability to obtain regulatory approval of, and ultimately commercialize, drug candidates; our ability to obtain, maintain, and enforce intellectual property protections; cyberattacks or other disruptions to our technology systems; our ability to attract, motivate, and retain key employees and manage our growth; inflation and other macroeconomic issues; and other risks and uncertainties such as those described under the heading "Risk Factors” in our filings with the U.S. Securities and Exchange Commission, including our Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. All forward-looking statements are based on management's current estimates, projections, and assumptions, and Recursion undertakes no obligation to correct or update any such statements, whether as a result of new information, future developments, or otherwise, except to the extent required by applicable law.

Unlike scores of people who scrambled for the blockbuster drugs Ozempic and Wegovy to lose weight in recent years, Danielle Griffin had no trouble getting them. The 38-year-old information technology worker from New Mexico had a prescription. Her pharmacy had the drugs in stock. And her health insurance covered all but $25 to $50 of the monthly cost. For Griffin, the hardest part of using the new drugs wasn’t access. It was finding out that the much-hyped medications didn’t really work for her. “I have been on Wegovy for a year and a half and have only lost 13 pounds,” said Griffin, who watches her diet, drinks plenty of water and exercises regularly. “I’ve done everything right with no success. It’s discouraging.” In clinical trials, most participants taking Wegovy or Mounjaro to treat obesity lost an average of 15% to 22% of their body weight — up to 50 pounds or more in many cases. But roughly 10% to 15% of patients in those trials were “nonresponders” who lost less than 5% of their body weight. Now that millions of people have used the drugs, several obesity experts told The Associated Press that perhaps 20% of patients — as many as 1 in 5 — may not respond well to the medications. It's a little-known consequence of the obesity drug boom, according to doctors who caution eager patients not to expect one-size-fits-all results. “It's all about explaining that different people have different responses,” said Dr. Fatima Cody Stanford, an obesity expert at Massachusetts General Hospital The drugs are known as GLP-1 receptor agonists because they mimic a hormone in the body known as glucagon-like peptide 1. Genetics, hormones and variability in how the brain regulates energy can all influence weight — and a person's response to the drugs, Stanford said. Medical conditions such as sleep apnea can prevent weight loss, as can certain common medications, such as antidepressants, steroids and contraceptives. “This is a disease that stems from the brain,” said Stanford. “The dysfunction may not be the same” from patient to patient. Despite such cautions, patients are often upset when they start getting the weekly injections but the numbers on the scale barely budge. “It can be devastating,” said Dr. Katherine Saunders, an obesity expert at Weill Cornell Medicine and co-founder of the obesity treatment company FlyteHealth. “With such high expectations, there’s so much room for disappointment.” That was the case for Griffin, who has battled obesity since childhood and hoped to shed 70 pounds using Wegovy. The drug helped reduce her appetite and lowered her risk of diabetes, but she saw little change in weight. “It’s an emotional roller coaster,” she said. “You want it to work like it does for everybody else.” The medications are typically prescribed along with eating behavior and lifestyle changes. It’s usually clear within weeks whether someone will respond to the drugs, said Dr. Jody Dushay, an endocrine specialist at Beth Israel Deaconess Medical Center. Weight loss typically begins right away and continues as the dosage increases. For some patients, that just doesn't happen. For others, side effects such as nausea, vomiting and diarrhea force them to halt the medications, Dushay said. In such situations, patients who were counting on the new drugs to pare pounds may think they’re out of options. “I tell them: It's not game over,” Dushay said. Trying a different version of the new class of drugs may help. Griffin, who didn't respond well to Wegovy, has started using Zepbound, which targets an additional hormone pathway in the body. After three months of using the drug, she has lost 7 pounds. “I'm hoping it's slow and steady,” she said. Other people respond well to older drugs, the experts said. Changing diet, exercise, sleep and stress habits can also have profound effects. Figuring out what works typically requires a doctor trained to treat obesity, Saunders noted. “Obesity is such a complex disease that really needs to be treated very comprehensively,” she said. “If what we’re prescribing doesn’t work, we always have a backup plan.” The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute’s Science and Educational Media Group. The AP is solely responsible for all content.Toronto makes another 'World's Best Cities' list. Here's where it ranks, plus which cities came out on topNone

Swiss National Bank Decreases Stock Holdings in Crane (NYSE:CR)

It's no secret that Nvidia ( NVDA 0.54% ) is one of the hottest artificial intelligence (AI) stocks in the market. The chip-making juggernaut just reported an incredible Q3, beating Wall Street's sky-high expectations. So why was the stock trading lower on Thursday when the market opened? Although it might seem to defy logic, it's not an uncommon phenomenon. Let's take a look at why it happens and see if the past might shed some light on what happens next. First, let's take a look at Nvidia's quarter. Even for Nvidia, this was a strong quarter Few companies have as much riding on their shoulders as Nvidia does in the current market. The company's performance is seen as a bellwether for the market as a whole. It's a good thing, then, that Nvidia delivered this quarter. Nvidia's data center segment continues to be the driving force behind its success, though its gaming arm is still showing solid growth. Demand for its Superchips and related hardware is at a fever pitch. As CEO Jensen Huang puts it, "The age of AI is in full steam, propelling a global shift to Nvidia computing." The big news is the confirmation that Blackwell, the newest iteration of its Superchips, is on schedule and will be rolled out without a hitch. During the earnings call, Huang made clear that the first chips are already "in the hands of all of [Nvidia's] major partners" and will soon be shipped to end users -- companies like Meta and Microsoft operate massive AI data centers. According to Huang, demand for Blackwell is "staggering"; Nvidia has so many orders it is struggling to keep pace. Despite this, demand for its current Hopper chips remains strong, and Huang indicated he believed orders would continue well into next year. Nvidia's reach is global Beyond the numbers, Nvidia highlighted some important developments that show the growing demand beyond U.S. commercial clients. Denmark just launched its first AI supercomputer driven by Nvidia's Hopper chips. This is an important client base for Nvidia that is often overshadowed by its success with big tech cloud operators. "Sovereign AI" -- world governments running their own computers -- could be a massive industry as nations around the world enter an information arms race. Nvidia is also finding commercial success worldwide, with new private companies in India, Japan, and Indonesia building Nvidia-powered AI data centers. Nvidia's stock dips In the initial hours after the market opened on Thursday, shares of Nvidia slipped, briefly reaching $141 after closing at nearly $146 the day before. Why would this happen after such a strong quarter? This is pretty common if Wall Street's expectations exceed the company's performance, even if that performance is solid. That's not what happened here. Nvidia beat estimates handily, delivering revenues of $35.1 billion and earnings per share (EPS) of $0.81. Consensus targets were $33.2 billion and $0.75, respectively. Here's the thing: market sentiment can exceed even Wall Street estimates. With all the hype around Nvidia and talk of "insane" demand for its new chips, it's becoming increasingly difficult for the company to live up to investors' expectations no matter what numbers it delivers. It's the curse of success. Nvidia has continuously beat estimates, so now, even when it does, it might not be by enough. Certain research has shown that investors tend to put too much faith in past earnings. Over time, this leads to a stock being overbought in the lead-up to an earnings release and a short-term dip after the release. What Nvidia is experiencing is very normal. Don't panic. The long-term potential is where we want to place most of our focus here and this report shows it is still firing on all cylinders. Given other stocks that have been in Nvidia's shoes and Nvidia itself last quarter -- shares dipped 18% in the days after earnings -- history tells us that the stock will be just fine.PPA Asia and MLP Asia Set to Launch, Bringing World-Class Pro Pickleball to the World's Most Populous Continent

Tile shop holdings sees $496k in stock purchases by investorsNo. 23 Alabama women beat Alabama State 83-33 at Emerald Coast Classic

ALPHARETTA, Ga.--(BUSINESS WIRE)--Dec 9, 2024-- Jackson Acquisition Company II (the “Company”) announced today that it priced its initial public offering of 20,000,000 units at $10.00 per unit. The units will be listed on the New York Stock Exchange (the “NYSE”) and will trade under the ticker symbol “JACS.U” beginning December 10, 2024. Each unit consists of one Class A ordinary share and one right to receive one-tenth (1/10) of a Class A ordinary share upon the consummation of an initial business combination. Once the securities comprising the units begin separate trading, the Class A ordinary shares and rights are expected to be listed on the NYSE under the symbols “JACS” and “JACS.R,” respectively. The offering is expected to close on December 11, 2024, subject to customary closing conditions. The Company, led by Chairman of the Board of Directors and Chief Executive Officer Richard L. Jackson, is a special purpose acquisition company formed for the purpose of effecting a merger, share exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses. While the Company may pursue an initial business combination in any industry, the Company intends to concentrate its search on businesses with a focus on healthcare services, healthcare technology, or otherwise focused on the healthcare industry. Roth Capital Partners is acting as sole book-running manager for the offering. The Company has granted the underwriter a 45-day option to purchase up to an additional 3,000,000 units to cover over-allotments, if any. The offering is being made only by means of a prospectus. When available, copies of the prospectus may be obtained from Roth Capital Partners, LLC, 888 San Clemente Drive, Suite 400, Newport Beach, CA 92660, (800) 678-9147 or by accessing the SEC’s website, www.sec.gov . A registration statement relating to the securities was declared effective by the Securities and Exchange Commission on December 9, 2024. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of, these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. Forward-Looking Statements This press release contains statements that constitute “forward-looking statements,” including with respect to the Company’s proposed initial public offering and the Company’s search for and/or completion of an initial business combination. No assurance can be given that the offering will be completed on the terms described, or at all, or that the Company will complete an initial business combination. Forward-looking statements are subject to numerous risks, conditions and other uncertainties, many of which are beyond the control of the Company, including those set forth in the Risk Factors section of the Company’s registration statement and preliminary prospectus for the Company’s offering filed with the U.S. Securities and Exchange Commission (the “SEC”). Copies of these documents are available on the SEC’s website, www.sec.gov . The Company undertakes no obligation to update these statements for revisions or changes after the date of this release, except as required by law. View source version on businesswire.com : https://www.businesswire.com/news/home/20241209829813/en/ CONTACT: Richard L. Jackson Jackson Acquisition Company II (678) 690-1079 KEYWORD: GEORGIA UNITED STATES NORTH AMERICA INDUSTRY KEYWORD: PROFESSIONAL SERVICES FINANCE SOURCE: Jackson Acquisition Company II Copyright Business Wire 2024. PUB: 12/09/2024 06:09 PM/DISC: 12/09/2024 06:09 PM http://www.businesswire.com/news/home/20241209829813/enMOSCOW: Russia fired a hypersonic intermediate-range ballistic missile at the city of Dnipro on Thursday (Nov 21) in response to the US and UK allowing Kyiv to strike Russian territory with advanced Western weapons, in a further escalation of the 33-month-old war. Russian President Vladimir Putin, in a televised address, said Moscow struck a Ukrainian military facility with a new ballistic missile known as "Oreshnik" (the hazel) and warned that more could follow. "A regional conflict in Ukraine previously provoked by the West has acquired elements of a global character," Putin said in an address to the nation carried by state television after 8pm Moscow time (1700 GMT). A US official said that Washington was pre-notified by Russia shortly before its strike, while another said they had briefed Kyiv and other close allies in recent days to prepare for the possible use of such a weapon. Earlier on Thursday, Kyiv said that Russia had fired an intercontinental ballistic missile (ICBM), a weapon designed for long-distance nuclear strikes and never before used in war, though US officials said it was an intermediate range ballistic missile that has a smaller range. Regardless of its classification, the latest strike highlighted rapidly rising tensions in the past several days. Ukraine fired US and British missiles at targets inside Russia this week despite warnings by Moscow that it would see such action as a major escalation. "Today there was a new Russian missile. All the characteristics - speed, altitude - are (of an) intercontinental ballistic (missile). An expert (investigation) is currently underway," Ukrainian President Volodymyr Zelenskyy said in a video statement. Ukraine's foreign ministry urged the international community to react swiftly to the use of what it said was "the use by Russia of a new type of weaponry." A US official, speaking on condition of anonymity, said Russia likely possesses a handful of the "experimental" intermediate-range ballistic missiles used in Thursday's strike. Ukraine's air force said the missile targeted Dnipro in central-eastern Ukraine and was fired from the Russian region of Astrakhan, more than 700km away. It did not specify what kind of warhead the missile had or what type of missile it was. There was no suggestion it was nuclear-armed. Intermediate-range ballistic missiles have a range of 3,000km to 5,500km. "Whether it was an ICBM or an IRBM, the range isn't the important factor," said Fabian Hoffmann, a doctoral research fellow at Oslo university who specialises in missile technology and nuclear strategy. "The fact that it carried a MIRVed (Multiple independently targetable reentry vehicle) payload is much more significant for signaling purposes and is the reason Russia opted for it. This payload is exclusively associated with nuclear-capable missiles." Russia also fired a Kinzhal hypersonic missile and seven Kh-101 cruise missiles, six of which were shot down, the Ukrainian air force said. The attack targeted enterprises and critical infrastructure in Dnipro, the air force said. Dnipro was a missile-making centre in the Soviet era. Ukraine has expanded its military industry during the war, but keeps its whereabouts secret. The air force did not say what the missile targeted or whether it had caused any damage, but regional governor Serhiy Lysak said the missile attack damaged an industrial enterprise and set off fires in Dnipro. Two people were hurt. Ukrainska Pravda, a Kyiv-based media outlet, had cited anonymous sources saying the missile was an RS-26 Rubezh, a solid-fuelled intercontinental ballistic missile with a range of 5,800km, according to the Arms Control Association. "TOTALLY UNPRECEDENTED" A group of glowing projectiles could be seen plummeting to the ground from the night sky in a video published by Come Back Alive, a Ukrainian military charity. It said the video was of Dnipro overnight. The NATO military alliance did not respond to a request for comment. The US European Command said it had nothing on the reported use of an ICBM and referred questions to the US Department of Defense. Some military experts said the missile launch, if confirmed, could be seen as an act of deterrence by Moscow following Kyiv's strikes into Russia with Western weapons this week, after restrictions on such strikes were lifted. Russian war correspondents on Telegram and an official speaking on condition of anonymity said Kyiv fired British Storm Shadow cruise missiles into Russia's Kursk region bordering Ukraine on Wednesday. Russia's defence ministry, in its daily report of events over the previous 24 hours on Thursday, said air defences had shot down two British Storm Shadow cruise missiles but did not say where. Britain had previously let Ukraine use Storm Shadows only within Ukrainian territory. Ukraine also fired US ATACMS missiles into Russia on Tuesday after US President Joe Biden gave the all-clear to use such missiles in this way, two months before he leaves office and Donald Trump returns to the White House. Putin on Tuesday lowered the threshold for a nuclear strike in response to a broader range of conventional attacks. Trump has said he will end the war, without saying how, and has criticised billions of dollars in aid for Ukraine under Biden. The warring sides believe Trump is likely to push for peace talks - not known to have been held since the war's earliest months - and are trying to attain strong positions before negotiations. Moscow has said the use of Western weapons to strike Russian territory far from the border would be a major escalation in the conflict. Kyiv says it needs the capability to defend itself by hitting Russian rear bases used to support Moscow's February 2022 invasion.